For Q2/10, GERN reported a net loss of $17 M, or $(0.18) per share. Q2/10 revenues were $1M. Total operating expenses for Q2/10 were $17.9 M with R&D expenses decreasing to $13.4 M as a result of reduced manufacturing costs associated with the completion of patient enrollment for the GRNVAC1 Phase 2 trial and lower preclinical study costs. G&A expenses increased to $4.5 M due to increased consulting costs and higher non-cash stock-based compensation expense. Interest and other income for Q2/10, amounted to $194,000. GERN ended the Q with $156 M in cash and investments.